Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ENPEP | Q07075 | 7/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | FPR2 | P25090 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445952 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL2543429 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL934499 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL1863400 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30052816 | 0.96 | ALDH1A1 (0.56) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30051944 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL29696992 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30051532 | 0.93 | ALDH1A1 (0.53) | ALDH1A1ENPEPL3MBTL1CA2CA1 | |
| SCHEMBL30011402 | 0.90 | ALDH1A1 (0.50) | ALDH1A1ENPEPL3MBTL1MMEACE | |
| SCHEMBL8975146 | 0.90 | ALDH1A1 (0.49) | ALDH1A1ENPEPL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | claimed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | claimed |
| US-20130225510-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2013-08-29 | — | — | US | claimed |
| EP-2630874-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2013-08-28 | — | — | EP | claimed |
| US-8486888-B2 | Methods for use of branched amino acids | NESTEC S.A. (CH) | 2013-07-16 | — | — | US | claimed |
| US-8329646-B2 | Methods for the treatment of muscle loss | NESTEC S.A. (CH) | 2012-12-11 | — | — | US | claimed |
| US-7989418-B2 | Methods for the use of branched chain amino acids | NESTEC S.A. (CH) | 2011-08-02 | — | — | US | claimed |
| EP-2340725-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2011-07-06 | — | — | EP | claimed |
| EP-1957061-B1 | COMBINATION COMPRISING AT LEAST ONE AMINO ACID AND A PKR INHIBITOR FOR USE IN THE TREATMENT OF MUSCLE LOSS | NESTEC SA (CH) | 2011-05-11 | — | — | EP | claimed |
| US-20110028392-A1 | METHODS FOR USE OF BRANCHED AMINO ACIDS | NESTEC S.A. (CH) | 2011-02-03 | — | — | US | claimed |
| US-20090170786-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2009-07-02 | — | — | US | claimed |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2009-04-23 | — | — | US | claimed |
| CN-101316582-A | Method of treating muscle loss | NESTEC SA (CH) | 2008-12-03 | — | — | CN | claimed |
| CN-101282657-A | Methods for the use of branched chain amino acids | NESTEC SA (CH) | 2008-10-08 | — | — | CN | claimed |
| EP-1957061-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2008-08-20 | — | — | EP | claimed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007064618-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2007-06-07 | — | — | WO | claimed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | claimed |
| US-20240426829-A1 | COMPOSITIONS AND METHODS FOR THE DETECTION OF BRAIN INJURY | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024243004-A2 | COMPOSITIONS AND METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-11-28 | — | — | WO | disclosed |
| US-12029713-B2 | Compositions and methods for the treatment of brain injury | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230190692-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2023-06-22 | — | — | US | disclosed |
| US-11589603-B2 | Powdered nutritional product containing branched-chain amino acids and a sugar alcohol | ABBOTT LABORATORIES (US) | 2023-02-28 | — | — | US | disclosed |
| US-11576885-B2 | Compositions and methods for the treatment of brain injury | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-02-14 | — | — | US | disclosed |
| EP-2925771-B1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL SCIENT IND RES (IN) | 2021-08-18 | — | — | EP | disclosed |
| US-20210030704-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2021-02-04 | — | — | US | disclosed |
| EP-2986113-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10690651-B2 | Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200170986-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT OF MEMORY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2020-06-04 | — | — | US | disclosed |
| US-20190167565-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS METHODS AND SYSTEMS | BEAUTY BIOLABS, LLC | 2019-06-06 | — | — | US | disclosed |
| US-10238597-B2 | Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems | BEAUTY BIOLABS LLC (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180255818-A1 | POWDERED NUTRITIONAL PRODUCT CONTAINING BRANCHED-CHAIN AMINO ACIDS AND A SUGAR ALCOHOL | ABBOTT LABORATORIES | 2018-09-13 | — | — | US | disclosed |
| US-20180133185-A1 | Compositions and Methods for the Improvement of Memory | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2018-05-17 | — | — | US | disclosed |
| US-20180003723-A1 | METHODS AND SYSTEMS FOR DIAGNOSING SLEEP DISORDERS | STEGIA AB (SE) | 2018-01-04 | — | — | US | disclosed |
| EP-3231435-A1 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS | Nestec S.A. (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9751911-B2 | Solomonamide analogue compounds, pharmaceuticals containing solomonamide analogue compounds, and processes for the preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2017-09-05 | — | — | US | disclosed |
| US-20170143621-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS, METHODS AND SYSTEMS | BEAUTY BIOLABS, LLC | 2017-05-25 | — | — | US | disclosed |
| WO-2017044601-A1 | POWDERED NUTRITIONAL PRODUCT CONTAINING BRANCHED-CHAIN AMINO ACIDS AND A SUGAR ALCOHOL | ABBOTT LABORATORIES (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2016044338-A2 | METHODS AND SYSTEMS FOR DIAGNOSING SLEEP DISORDERS | OASIS DIAGNOSTICS CORPORATION (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160058726-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2016-03-03 | — | — | US | disclosed |
| EP-2986113-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | The Children's Hospital of Philadelphia (US) | 2016-02-24 | — | — | EP | disclosed |
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-10-15 | — | — | US | disclosed |
| EP-2925771-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | Council of Scientific & Industrial Research (IN) | 2015-10-07 | — | — | EP | disclosed |
| CN-104936597-A | Antidementia and learning/memory function-improving drug | SUNTORY HOLDINGS LTD | 2015-09-23 | — | — | CN | disclosed |
| US-8980548-B2 | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same | METABOLON, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| WO-2014172341-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2014-10-23 | — | — | WO | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140296134-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776829-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | The Board of Regents of The University of Texas System (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-1973042-B | Process for producing dipeptide | KYOWA HAKKO KOGYO KK | 2014-09-17 | — | — | CN | disclosed |
| WO-2014083578-A1 | A PROCESS FOR THE PREPARATION OF SOLOMONAMIDE ANALOGUES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESERACH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2014-06-05 | — | — | WO | disclosed |
| CN-103642882-A | Process for producing dipeptides | KYOWA HAKKO KOGYO KK | 2014-03-19 | — | — | CN | disclosed |
| US-20130225510-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2013-08-29 | — | — | US | disclosed |
| US-20130225510-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2630874-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2013-08-28 | — | — | EP | disclosed |
| EP-2630874-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-8486888-B2 | Methods for use of branched amino acids | NESTEC S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8486888-B2 | Methods for use of branched amino acids | NESTEC S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070962-A1 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130115649-A1 | Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same | METABOLON, INC. | 2013-05-09 | — | — | US | disclosed |
| US-8329646-B2 | Methods for the treatment of muscle loss | NESTEC S.A. (CH) | 2012-12-11 | — | — | US | disclosed |
| CN-102647990-A | Methods of attenuating the loss of functional status | NESTEC SA | 2012-08-22 | — | — | CN | disclosed |
| US-20120195873-A1 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS | NESTEC S.A. (CH) | 2012-08-02 | — | — | US | disclosed |
| EP-2456448-A1 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS | Nestec S.A. (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-7989418-B2 | Methods for the use of branched chain amino acids | NESTEC S.A. (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989418-B2 | Methods for the use of branched chain amino acids | NESTEC S.A. (CH) | 2011-08-02 | — | — | US | disclosed |
| EP-2340725-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2011-07-06 | — | — | EP | disclosed |
| EP-2340725-A1 | Methods for the use of branched chain amino acids | Nestec S.A. (CH) | 2011-07-06 | — | — | EP | disclosed |
| EP-1957061-B1 | COMBINATION COMPRISING AT LEAST ONE AMINO ACID AND A PKR INHIBITOR FOR USE IN THE TREATMENT OF MUSCLE LOSS | NESTEC SA (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20110028392-A1 | METHODS FOR USE OF BRANCHED AMINO ACIDS | NESTEC S.A. (CH) | 2011-02-03 | — | — | US | disclosed |
| US-20110028392-A1 | METHODS FOR USE OF BRANCHED AMINO ACIDS | NESTEC S.A. (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011011252-A1 | METHODS OF ATTENUATING THE LOSS OF FUNCTIONAL STATUS | NESTEC S.A. (CH) | 2011-01-27 | — | — | WO | disclosed |
| US-7846902-B2 | Dipeptide-comprising composition for oral administration | KYOWA HAKKO BIO CO., LTD. (JP) | 2010-12-07 | — | — | US | disclosed |
| CN-101715484-A | Method for producing dipeptide | KYOWA HAKKO KOGYO KK | 2010-05-26 | — | — | CN | disclosed |
| US-20090306340-A1 | METHOD FOR PURIFICATION OF OLIGOPEPTIDES | KYOWA HAKKO BIO CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101479292-A | Method for purification of oligopeptide | KYOWA HAKKO BIO CO LTD (JP) | 2009-07-08 | — | — | CN | disclosed |
| US-20090170786-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2009-07-02 | — | — | US | disclosed |
| US-20090170786-A1 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2009-07-02 | — | — | US | disclosed |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-2036919-A1 | METHOD FOR PURIFICATION OF OLIGOPEPTIDE | Kyowa Hakko Bio Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080305151-A1 | Dipeptide-Comprising Composition for Oral Administration | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| CN-101316582-A | Method of treating muscle loss | NESTEC SA (CH) | 2008-12-03 | — | — | CN | disclosed |
| CN-101282657-A | Methods for the use of branched chain amino acids | NESTEC SA (CH) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282657-A | Methods for the use of branched chain amino acids | NESTEC SA (CH) | 2008-10-08 | — | — | CN | disclosed |
| CN-100422207-C | Process for producing dipeptide L-amino acid amide hydrolase to be used therein and process for producing L-amino acid amide hydrolase | AJINOMOTO KK (JP) | 2008-10-01 | — | — | CN | disclosed |
| EP-1957061-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2008-08-20 | — | — | EP | disclosed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940252-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2008-07-09 | — | — | EP | disclosed |
| EP-1941896-A1 | DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| CN-101087878-A | Mutant protein having the peptide-synthesizing activity | AJINOMOTO KK (JP) | 2007-12-12 | — | — | CN | disclosed |
| WO-2007053390-A3 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NOVARTIS AG (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007064618-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | NESTEC S.A. (CH) | 2007-06-07 | — | — | WO | disclosed |
| CN-1973042-A | Process for producing dipeptide | KYOWA HAKKO KOGYO KK (JP) | 2007-05-30 | — | — | CN | disclosed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053390-A2 | METHODS FOR THE USE OF BRANCHED CHAIN AMINO ACIDS | NESTEC S.A. (CH) | 2007-05-10 | — | — | WO | disclosed |
| CN-1535279-A | Process for producing dipeptide L-amino acid amide hydrolase to be used therein and process for producing L-amino acid amide hydrolase | ֮����ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5612002-A | SYNTHESIS OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5593642-A | CONTAINMENT OF SOLID SUPPORT WITHIN A GAS DISPERSION TUBE | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5582801-A | HAVING PLURALITY OF REACTION TUBES WITH FILTERS ON LOWER ENDS, RESERVOIR WITH MEANS FOR RECEIVING FILTERS, HOLDER FOR SUPPORTING TUBES, MANIFOLD ENCLOSING UPPER ENDS, FASTENERS HOLDING TOGETHER HOLDER AND MANIFOLD, HOLDER AND RESERVOIR | WARNER-LAMBERT COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5567391-A | MULTICOMPARTMENT CHEMICAL REACTORS | WARNER-LAMBERT COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565173-A | USED FOR SOLID-PHASE SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5374551-A | Measurement of metabolism of alpha-methyl glucoside | BIOLOG, INC. (US) | 1994-12-20 | — | — | US | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291659-A1 | SOLOMONAMIDE ANALOGUE COMPOUNDS, PHARMACEUTICALS CONTAINING SOLOMONAMIDE ANALOGUE COMPOUNDS, AND PROCESSES FOR THE PREPARATION THEREOF | CNR2, SRM, CNR1 | ALDH1A1 3504/4885ENPEP 3108/4885L3MBTL1 4793/4885 |
| US-20090105123-A1 | METHODS FOR THE TREATMENT OF MUSCLE LOSS | BCAT2, CPT1B, BCAT1 | ALDH1A1 3467/4885ENPEP 107/4885L3MBTL1 354/4885 |
| US-10238597-B2 | Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems | CUTA, IL17A, TSLP | ALDH1A1 579/4885ENPEP 1036/4885L3MBTL1 3908/4885 |
| US-20190167565-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS METHODS AND SYSTEMS | CUTA, IL17A, MMP11 | ALDH1A1 580/4885ENPEP 975/4885L3MBTL1 3743/4885 |
| US-20170143621-A1 | PROBIOTIC TREATMENT OF SKIN DISEASES, DISORDERS, AND INFECTIONS: FORMULATIONS, METHODS AND SYSTEMS | CUTA, IL17A, TSLP | ALDH1A1 579/4885ENPEP 1036/4885L3MBTL1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.